SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
NEW ORLEANS, Nov. 08, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 3, 2017 to file lead plaintiff applications in securities class action lawsuits against Allergan plc (NYSE:AGN), if they purchased the Company’s securities between February 25, 2014 and November 3, 2016, inclusive (the “Class Period”). This action is pending in the United States District Courts for the Central District of California and Southern District of New York.
What You May Do
If you purchased shares of Allergan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 3, 2017.
About the Lawsuit
Allergan and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On November 3, 2016, Bloomberg reported that an “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies,” including Allergan’s former generic pharmaceuticals unit Actavis, “and about two dozen drugs.” The article further stated that a “grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year.” Additionally, according to Bloomberg, “[g]eneric drug companies are also contending with a civil price-fixing investigation by [the] Connecticut Attorney General.”
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
